Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163121 | 0.88 | HDAC2 (0.42) | ABCB1ABCG2HDAC2ADORA2AGPR119 | |
| SCHEMBL20163035 | 0.87 | HDAC3 (0.44) | ABCB1ABCG2HDAC3HDAC2ADORA2A | |
| SCHEMBL20163026 | 0.87 | GBA1 (0.45) | HDAC3HDAC2GPR119TGFBR1CYP1A2 | |
| SCHEMBL20163018 | 0.86 | ABCB1 (0.45) | ABCB1ABCG2HDAC2ADORA2AGPR119 | |
| SCHEMBL20163043 | 0.83 | GPR119 (0.43) | ABCB1ABCG2HDAC3HDAC2ADORA2A | |
| SCHEMBL20163087 | 0.81 | ABCB1 (0.44) | ABCB1ABCG2ADORA2AGPR119ADORA1 | |
| SCHEMBL20163094 | 0.81 | ADORA2A (0.45) | ABCB1ABCG2HDAC3HDAC2ADORA2A | |
| SCHEMBL20163111 | 0.81 | ABCB1 (0.43) | ABCB1ABCG2HDAC3HDAC2ADORA2A | |
| SCHEMBL20163081 | 0.80 | HDAC2 (0.58) | ABCB1ABCG2HDAC3HDAC2ADORA2A | |
| SCHEMBL20163100 | 0.79 | ADORA2A (0.47) | ABCB1ABCG2ADORA2AGPR119ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2022-09-08 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| EP-3544969-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018098296-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | ABCB1 1564/4885ABCG2 2230/4885HDAC3 7/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | ABCB1 1376/4885ABCG2 2489/4885HDAC3 8/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | ABCB1 3175/4885ABCG2 2968/4885HDAC3 6/4885 |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | ABCB1 2283/4885ABCG2 2470/4885HDAC3 7/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | ABCB1 2167/4885ABCG2 2524/4885HDAC3 7/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | ABCB1 2283/4885ABCG2 2470/4885HDAC3 7/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | ABCB1 3175/4885ABCG2 2968/4885HDAC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.